To discuss the the data from the SCORED and SOLOIST-WHF phase 3 clinical trials on Lexicon's recently approved dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin) with a cardiologist.
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Delving into the data from the SCORED and SOLOIST-WHF phase 3 clinical trials on Lexicon's recently approved dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin).
Ticker(s): LXRXWho's the expert?
Institution: Baylor University
- Professor of Medicine and Associate Chief of Cardiology
- Studies the molecular mechanisms of cardiovascular development in understanding of heart development for the creation of novel regenerative approaches to treat heart diseases.
- Research Interests include; Cardiac Regeneration, Advanced Heart Failure, and Mechanical Circulatory Support.
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
